Salmonella typhimurium outbreak in a neonatal unit in Turkey

Department of Pediatrics, Tepecik Educational and Research Hospital, Izmir, Turkey.
The Indian Journal of Pediatrics (Impact Factor: 0.87). 04/2009; 76(6):629-33. DOI: 10.1007/s12098-009-0083-4
Source: PubMed


To analyze an outbreak caused by a multiple resistant strain of S. typhimurium in a newborn unit in Turkey.
The outbreak occurred during the period 15 to 29 March,2005. A newborn infected with S. typhimurium was defined as a case. Newborns who were hospitalized during the outbreak period with no diagnosis of S. typhimurium infections (n=50) constituted the control group I (CG I). The matched patients of the control group II (CG II) (n=20) were selected from neonates without S. typhimurium infections during the period.
Of 22 infants who were affected two died. Cases developed diarrhea (n=20), septicemia (n=5) and meningitis (n=1). The strain was resistant to ampicillin, ceftriaxone, ceftazidime, amikacin, trimethoprim-sulfamethoxasole and chloramphenicol, susceptible to meropenem. All of the infected neonates were treated with meropenem. The surveillance cultures were negative. The outbreak was controlled by appropriate therapy and institution of effective control measures. The cases were more exposed to mechanical ventilation than CG I (p<0.05). The mean additional length of stay in cases was significantly different from CG II (14.9 days vs. 5.1 days, p<0.05). The mean charges was $1588.78 for a case and $506.94 for a control (P<0.05). Accommodation accounted for 44.5% of these extra charges.
This study increases the understanding of the burden of multidrug-resistant S. typhimurium infection. Nosocomial outbreaks have a major effect on healthcare delivery, costs and outcomes.

Download full-text


Available from: Ayse Berna Anil, Jan 24, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infections acquired in the intensive care unit (ICU) are associated with significant morbidity and mortality. Using surveillance data collected in the United States and internationally, we describe contemporary rates, sites, and pathogens responsible for common ICU-acquired infections. Emerging pathogens are outlined, including a systematic review of published ICU infection outbreaks from 2005 to 2010. Compared with a similar review of outbreaks conducted in 2003, multiresistant gram-negative bacteria (eg, ACINETOBACTER and PSEUDOMONAS species) were more commonly reported, whereas resistant STAPHYLOCOCCUS AUREUS was reported less frequently. Advances in ICU infection prevention, including central line bundles, chlorhexidine body wash, and hand hygiene interventions occurred during this period. We also describe how changes in the pattern of antimicrobial use can affect the prevalence of multiresistant pathogens.
    Seminars in Respiratory and Critical Care Medicine 04/2011; 32(2):115-38. DOI:10.1055/s-0031-1275525 · 2.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Our objective was to determine the quality of literature in costing of the economic burden of patient safety. We selected 15 types of patient safety targets for our systematic review. We searched the literature published between 2000 and 2010 using the following terms: "costs and cost analysis," "cost-effectiveness," "cost," and "financial management, hospital." We appraised the methodologic quality of potentially relevant studies using standard economic methods. We recorded results in the original currency, adjusted for inflation, and then converted to 2010 US dollars for comparative purposes (2010 US$1.00 = 2010 €0.76). The quality of each costing study per patient safety target was also evaluated. We screened 1948 abstracts, and identified 158 potentially eligible studies, of which only 61 (39%) reported any costing methodology. In these 61 studies, we found wide estimates of the attributable costs of patient safety events ranging from $2830 to $10,074. In general hospital populations, the cost per case of hospital-acquired infection ranged from $2132 to $15,018. Nosocomial bloodstream infection was associated with costs ranging from $2604 to $22,414. There are wide variations in the estimates of economic burden due to differences in study methods and methodologic quality. Greater attention to methodologic standards for economic evaluations in patient safety is needed.
    Drug, Healthcare and Patient Safety 10/2012; 4:141-65. DOI:10.2147/DHPS.S33288
  • Source

    AHRQ Publication No. 12-EHC071-EF. 08/2012; Agency for Healthcare Research and Quality.
Show more